Biotech Values

[DewDiligence]

Thanks for the additional analysis of this practice from the issuing company’s perspective. No matter how you slice it, I think option exercising while an insider is in possession of material nonpublic information is ethically wrong and the loophole that allows it ought to be closed. I doubt that it will be, however.